Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
784 participants
INTERVENTIONAL
2020-11-01
2023-12-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The present randomized controlled study aims to compare between a constant estrogen dose protocol and a step-wise increasing estrogen dose protocol on the live birth rate of HRT-FET cycles.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study:the Different Outcomes Between Natural Cycle and Hormone Replacement Cycle in FET
NCT01780558
Serum Progesterone Level in HRT-FET：a RCT
NCT04248309
The Effects of Two Endometrium Preparation Protocols in Frozen-thawed Embryo Transfer in Women With Irregular Cycles
NCT01780610
Progesterone Supplementation on Women Having Low Progesterone Levels on Transfer Day
NCT04897269
Association Between Live Birth Rate and Serum Progesterone During Hormonal Replacement Therapy
NCT05588635
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
This is a multicenter randomized controlled trial. Women undergoing HRT-FET will be recruited and randomized to use a constant estrogen dose protocol and a step-wise increasing estrogen dose protocol.
Participation in the study is totally voluntary. The subjects can withdraw from the study at any time and they will still receive standard medical care.
Women being scheduled for HRT-FET will be assessed for eligibility. Eligible women will be recruited in the study and each woman will only be included in the study once.
Informed written consent will be obtained prior to recruitment. The baseline characteristics will be collected. Transvaginal ultrasound will be done to measure the endometrial thickness on the day of progesterone supplementation. Embryo transfer will be performed 3 days or 5 days after progesterone use, depending on replacement of cleaving stage embryos or blastocysts respectively.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Constant group
Women will receive oral estradiol valerate (Progynova®; Bayer Schering Pharma AG, Berlin, Germany) 3 mg bid for 14 days for endometrial priming from the second or third day of the menstrual cycle.
different estrogen supplementation modes
The different estrogen supplementation modes are randomized into two groups.
Step -up group
Women will receive estradiol valerate 2mg once daily for 4 days from the second to fifth day,followed by 2mg bid for 4 days from the sixth to ninth day and then 3mg bid for 6 days from tenth to fifteenth day of menstrual cycle.
different estrogen supplementation modes
The different estrogen supplementation modes are randomized into two groups.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
different estrogen supplementation modes
The different estrogen supplementation modes are randomized into two groups.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Replacing 1-2 early cleavage embryos or blastocysts after thawing.
Exclusion Criteria
* Use of donor oocytes
* Hydrosalpinx shown on pelvic scanning and not surgically treated such as tubal ligation or resection
* Severe uterine adhesion
* The endometrial thickness cannot reach 8mm in previous fresh cycles or HRT -FET cycles
20 Years
42 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Haiyan Lin
Attending physician
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Yi Zhang
Role: STUDY_CHAIR
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
HRT-E2
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.